These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Jiang X; Dalebout TJ; Bredenbeek PJ; Carrion R; Brasky K; Patterson J; Goicochea M; Bryant J; Salvato MS; Lukashevich IS Vaccine; 2011 Feb; 29(6):1248-57. PubMed ID: 21145373 [TBL] [Abstract][Full Text] [Related]
27. Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Branco LM; Grove JN; Boisen ML; Shaffer JG; Goba A; Fullah M; Momoh M; Grant DS; Garry RF Virol J; 2011 Oct; 8():478. PubMed ID: 22023795 [TBL] [Abstract][Full Text] [Related]
28. Advanced vaccine candidates for Lassa fever. Lukashevich IS Viruses; 2012 Oct; 4(11):2514-57. PubMed ID: 23202493 [TBL] [Abstract][Full Text] [Related]
29. Routine and pulse vaccination for Lassa virus could reduce high levels of endemic disease: A mathematical modelling study. Davies J; Lokuge K; Glass K Vaccine; 2019 Jun; 37(26):3451-3456. PubMed ID: 31088745 [TBL] [Abstract][Full Text] [Related]
30. Bacterial-based systems for expression and purification of recombinant Lassa virus proteins of immunological relevance. Branco LM; Matschiner A; Fair JN; Goba A; Sampey DB; Ferro PJ; Cashman KA; Schoepp RJ; Tesh RB; Bausch DG; Garry RF; Guttieri MC Virol J; 2008 Jun; 5():74. PubMed ID: 18538016 [TBL] [Abstract][Full Text] [Related]
31. Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot. Mateo M; Reynard S; Carnec X; Journeaux A; Baillet N; Schaeffer J; Picard C; Legras-Lachuer C; Allan R; Perthame E; Hillion KH; Pietrosemoli N; Dillies MA; Barrot L; Vallve A; Barron S; Fellmann L; Gaillard JC; Armengaud J; Carbonnelle C; Raoul H; Tangy F; Baize S Sci Transl Med; 2019 Oct; 11(512):. PubMed ID: 31578242 [TBL] [Abstract][Full Text] [Related]
32. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Robinson JE; Hastie KM; Cross RW; Yenni RE; Elliott DH; Rouelle JA; Kannadka CB; Smira AA; Garry CE; Bradley BT; Yu H; Shaffer JG; Boisen ML; Hartnett JN; Zandonatti MA; Rowland MM; Heinrich ML; Martínez-Sobrido L; Cheng B; de la Torre JC; Andersen KG; Goba A; Momoh M; Fullah M; Gbakie M; Kanneh L; Koroma VJ; Fonnie R; Jalloh SC; Kargbo B; Vandi MA; Gbetuwa M; Ikponmwosa O; Asogun DA; Okokhere PO; Follarin OA; Schieffelin JS; Pitts KR; Geisbert JB; Kulakoski PC; Wilson RB; Happi CT; Sabeti PC; Gevao SM; Khan SH; Grant DS; Geisbert TW; Saphire EO; Branco LM; Garry RF Nat Commun; 2016 May; 7():11544. PubMed ID: 27161536 [TBL] [Abstract][Full Text] [Related]